Navigation Links
Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients
Date:6/1/2009

ur weeks, respectively, achieved clinical remission as measured by the CDAI.

No new or unexpected safety signals were observed in this study. Adverse events were previously reported from the WELCOME study: the most common adverse events were headache, nasopharyngitis and nausea. The incidence of serious adverse events (SAEs) was seven percent and the most frequent SAEs involved gastrointestinal disorders (five percent) and infections and infestations (2 percent).

Additional data from the WELCOME study presented at DDW, includes:

  • Health-related Quality of Life: Cimzia(R) (400 mg) administered at every two or four weeks similarly improved patient-reported health-related quality of life as measured by the Inflammatory Bowel Disease Questionnaire (a validated tool assessing bowel symptoms, systematic symptoms, emotional function and social function) by Week 26. (Abstract #S1058)
  • Efficacy Independent of IFX Dosing: Cimzia(R) (400 mg) was efficacious in rapidly inducing a clinical response in the infliximab-refractory patient population regardless of the previous dosages of infliximab. (Abstract #S1064)

"As we continue to study Cimzia(R)'s potential efficacy, we are pleased to be adding to an impressive body of data that supports the use of Cimzia(R) for a variety of moderate to severe Crohn's disease patients," said David Robinson, vice president and general manager of UCB's Immunology Business Unit.

Recently, UCB announced that Cimzia(R) is now available to Crohn's patients in a pre-filled syringe, developed in partnership with OXO Good Grips(R) for subcutaneous self-administration once every four weeks after initial dosing. Cimzia(R), manufactured by UCB, was approved by the U.S. Food and Drug Administration on April 22, 2008.

About WELCOME

The WELCOME study is a 539 pa
'/>"/>

SOURCE UCB, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. New Data Suggest CIMZIA(R) (Certolizumab Pegol) Active in Treating Moderate to Severe Crohns Patients With Fistulizing Disease
2. FDA Agrees to Review Cimzia(R) File for the Treatment of Rheumatoid Arthritis
3. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
4. Reorganizational Healing Provides Access to Greater Quality of Life, Reduced Stress
5. Cumberland Pharmaceuticals Provides Hospital In-Service Webcast for Acetadote(R)
6. Resverlogix Provides Quarterly Update
7. China Sky One Medical, Inc. Provides Update on Filing Form 10-K
8. Amylin Pharmaceuticals Provides Shareholders with Update Regarding Recent Developments
9. US Oncology Provides Full Service Management of Clinical Trials
10. SemBioSys provides update on insulin program
11. Cochlear Americas Provides Support for Cochlear Implant Recipients to Pursue Higher Education
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... The ability to see through organs and even the ... well as fine-grained cellular structures has been a long-time ... Press July 31st in the journal Cell ... simple methods for making opaque organs, bodies, and human ... connections intact. The protocols could pave the way for ...
(Date:7/31/2014)... Colo. , July 31, 2014 ... awardee today with $25,000 to fund a translational ... inception in 2011, the gift was presented at ... Annual Meeting in Colorado Springs, ... specialize in neurointerventional approaches to neurovascular conditions, SNIS ...
(Date:7/31/2014)... 2014 Graphite Metallizing Corporation announces ... carts. These bearings are uniquely suited to prevent loss ... because of the high temperatures . , Recently, ... the design engineers at Graphite Metallizing to overcome problems ... their manufacturing operation, pans containing blocks of powder mixture ...
(Date:7/31/2014)... 2014 Research and Markets has ... 2014-2018" report to their offering. ... study of the genetic material or genomes of an ... for the discovery and development of diagnostic and therapeutic ... conditions. Genomics is supported by three major product segments: ...
Breaking Biology Technology:See-through organs and bodies will accelerate biomedical discoveries 2SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 2SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 3Graphite Metallizing Announces Bearings for High Temperature Oven Applications 2Graphite Metallizing Announces Bearings for High Temperature Oven Applications 3Global Genomics Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Life Technologies, Qiagen and Illumina 2
... of Magainins, the first of a new class of anti-infectives, ... advise Company on pexiganan ... Bulletin Board: MACM) today announced that following its,acquisition of rights ... Board. Dr. Zasloff discovered magainins in,the skin of the African ...
... 24, at 1:30 p.m. EDT, ALAMEDA, Calif., ... a biopharmaceutical company developing innovative therapies,for the treatment ... to discuss third quarter results on Wednesday, October ... Kenneth Chahine, Chief Executive,Officer, and Michael Coffee, Chief ...
... Kyphon Inc.,(Nasdaq: KYPH ) announced today that its ... Inc. (NYSE: MDT ) at a special,meeting of ... 26, 2007, Kyphon entered into a,definitive merger agreement with ... the outstanding shares of Kyphon common stock for,$71.00 per ...
Cached Biology Technology:MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Company's Scientific Advisory Board 2MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Company's Scientific Advisory Board 3MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Company's Scientific Advisory Board 4MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Company's Scientific Advisory Board 5Avigen, Inc. Announces Third Quarter 2007 Earnings Conference Call 2Kyphon Stockholders Approve Merger with Medtronic 2
(Date:7/31/2014)... United States, natural-gas production from shale rock has ... Yet scientists still do not fully understand the ... a report in the journal Frontiers in ... extraction continues to vastly outpace scientific examination, a ... and institutions, including Princeton University, concluded that determining ...
(Date:7/31/2014)... nearly 3,000 genes to the earliest common ancestor ... have created an extensive "Tree of Lepidoptera" in ... sequencing. , Among the study,s more surprising ... moths than to large ones, which completely changes ... also found that some insects once classified as ...
(Date:7/31/2014)... NCT00518336) shows the sustained efficacy, immunogenicity and ... vaccine Cervarix. Women vaccinated with the HPV-16/18 ... nine years, and vaccine efficacy (VE) against ... longest follow-up report for a licensed HPV ... full paper. , HPV and vaccination ...
Breaking Biology News(10 mins):'Fracking' in the dark: Biological fallout of shale-gas production still largely unknown 2'Fracking' in the dark: Biological fallout of shale-gas production still largely unknown 3UF study advances 'DNA revolution,' tells butterflies' evolutionary history 2UF study advances 'DNA revolution,' tells butterflies' evolutionary history 3Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 3
... ANN ARBOR, Mich.---University of Michigan School of Dentistry has ... may be the largest clinical study to date using genetic ... William Giannobile, professor at U-M dentistry and director of the ... Dentistry, will lead the study for U-M. "It,s ...
... and Building Media Inc. (BMI), a DuPont subsidiary, will ... help dramatically improve the energy efficiency of American homes ... 15 teams, appointed by the U.S. Department of Energy ... million for the initial 18 months to deliver innovative ...
... July 27, 2010 Innovotech Inc. (TSX-V: IOT), a pioneer ... exclusive distribution agreement with LevPharm Ltd of Israel to market ... within Israel. "We are very excited to enter into ... bioFILM PA test can have on improving patient care while ...
Cached Biology News:Landmark dental school study uses genetic test to help predict gum disease 2NJIT to help lead public/private partnership to develop high-efficiency homes 2
KAI 1 (G-2)...
Anti-Mouse Valpha 2 TCR, Purified (Clone B20.1) (rat IgG2a)...
Anti-OSMR Monoclonal Antibody Research Focus: cytokine/growth factor Storage: 4C Shipping Temperature: 4C...
... are designed for use with the ProQuest ... MaV203 contains deletions in the endogenous GAL4 ... two-hybrid systems. The strain also has leu2 ... bait and prey vectors. MaV203 contains three ...
Biology Products: